{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:38:38Z","timestamp":1761093518536,"version":"build-2065373602"},"reference-count":19,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T00:00:00Z","timestamp":1651622400000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Study Objective<\/jats:title><jats:p>The objective of this study was to determine the clinical relationship between proton pump inhibitor (PPI) use and sustained virologic response (SVR) in patients treated with sofosbuvir\/velpatasvir (SOF\/VEL) for chronic hepatitis C virus (HCV) infection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>This was a multicenter retrospective cohort study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>Data was collected on patients from 128 Veterans Affairs Medical Centers throughout the United States.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients<\/jats:title><jats:p>This study included veterans aged 18\u201089 years with viremic HCV who received a full course of SOF\/VEL treatment from June 2016 \u2013 July 2017.<\/jats:p><\/jats:sec><jats:sec><jats:title>Intervention<\/jats:title><jats:p>Sustained viral response was compared in patients taking SOF\/VEL with or without concurrent PPI prescriptions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Measurements and Main Results<\/jats:title><jats:p>Analysis of the primary outcome was completed utilizing logistic regression. The relationship between SVR and PPI use was adjusted for African\u2010American race, presence of cirrhosis, prior treatment, BMI greater than 30 kg\/m2, and HCV genotype. The final analysis included 4,008 veterans, 830 with concomitant PPI use and 3,178 without PPI use. After adjustment for other variables in the logistic model, there was no statistically significant association between PPI use and lower SVR (odds ratio 0.67; 95%CI: 0.42, 1.06; <jats:italic>p<\/jats:italic>\u00a0=\u00a00.087).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Concomitant PPI treatment adjusted for other variables did not significantly impact success or failure of SOF\/VEL treatment of chronic HCV. Despite the lack of significant association identified in this study, in efforts to provide the best care possible, it remains prudent to proceed with caution in patients desiring to use PPI therapy while receiving SOF\/VEL, and ensure prescribing instructions are closely followed in regard to concomitant PPI use, especially in patients with other risk factors for decreased SVR.<\/jats:p><\/jats:sec>","DOI":"10.1002\/phar.2682","type":"journal-article","created":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T04:25:54Z","timestamp":1649478354000},"page":"397-404","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of proton pump inhibitors on sustained virologic response in veterans treated with sofosbuvir\/velpatasvir for chronic hepatitis C virus: A retrospective cohort study"],"prefix":"10.1002","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3494-5347","authenticated-orcid":false,"given":"Danielle M.","family":"Rumph","sequence":"first","affiliation":[{"name":"Battle Creek Veterans Affairs Medical Center  Battle Creek Michigan USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig M.","family":"Straley","sequence":"additional","affiliation":[{"name":"Battle Creek Veterans Affairs Medical Center  Battle Creek Michigan USA"},{"name":"College of Pharmacy Ferris State University  Big Rapids Michigan USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny L.","family":"Kolberg","sequence":"additional","affiliation":[{"name":"Battle Creek Veterans Affairs Medical Center  Battle Creek Michigan USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Jacob","sequence":"additional","affiliation":[{"name":"Pharmacy Service Veterans Integrated Service Network 17  Arlington Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,5,4]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30297"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3117"},{"key":"e_1_2_7_4_1","unstructured":"Epclusa [Package Insert]. Gilead Sciences;2016."},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512612"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28901"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0037521"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.51.1.89"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.08.004"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512614"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27937"},{"key":"e_1_2_7_12_1","unstructured":"US Food and Drug Administration Center for Drug Evaluation and Research.Application Number: 208341Orig1s000. Clinical Pharmacology and Biopharmaceutics Review(s);2016. Accessed May 15 2017.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/208341Orig1s000ClinPharmR.pdf"},{"key":"e_1_2_7_13_1","unstructured":"Prilosec [Package Insert]. AstraZeneca Pharmaceuticals LP;2012."},{"issue":"9","key":"e_1_2_7_14_1","first-page":"1239","article-title":"Prevalence of drug\u2010drug interactions with pangenotypic direct\u2010acting antivirals for hepatitis C and real\u2010world care management in the United States: a retrospective observational study","volume":"27","author":"Currry MP","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21178"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(96)00236-3"},{"issue":"4","key":"e_1_2_7_17_1","first-page":"327","article-title":"Efficacy and safety of direct\u2010acting antivirals in hepatitis C virus\u2010infected patients taking proton pump inhibitors","volume":"5","author":"Wijarnpreecha K","year":"2017","journal-title":"J Clin Transl Hepatol"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28782"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13462"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512610"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2682","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/phar.2682","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2682","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:42:40Z","timestamp":1761046960000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1002\/phar.2682"],"URL":"https:\/\/doi.org\/10.1002\/phar.2682","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"2021-12-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}